Tetraphase Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTPH)

$6.15 0.31 (5.31 %)
(As of 12/11/2017 12:10 PM ET)
Previous Close$5.84
Today's Range$5.79 - $6.20
52-Week Range$3.57 - $9.93
Volume539,100 shs
Average Volume706,511 shs
Market Capitalization$316.20 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Receive TTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TTPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TTPH
CUSIPN/A
Phone617-715-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio7.55%
Quick Ratio7.55%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.14 million
Price / Sales61.52
Cash FlowN/A
Price / CashN/A
Book Value$3.79 per share
Price / Book1.62

Profitability

Trailing EPS($2.86)
Net Income$-77,480,000.00
Net Margins-1,382.33%
Return on Equity-88.27%
Return on Assets-77.53%

Miscellaneous

Employees66
Outstanding Shares51,420,000

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Frequently Asked Questions

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.63). The biopharmaceutical company had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm's quarterly revenue was up 355.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) EPS. View Tetraphase Pharmaceuticals' Earnings History.

When will Tetraphase Pharmaceuticals make its next earnings announcement?

Tetraphase Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Tetraphase Pharmaceuticals.

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?

5 brokers have issued 1 year price targets for Tetraphase Pharmaceuticals' shares. Their forecasts range from $13.00 to $24.00. On average, they anticipate Tetraphase Pharmaceuticals' stock price to reach $17.00 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.

Who are some of Tetraphase Pharmaceuticals' key competitors?

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Chairman of the Board of Directors (Age 74)
  • Guy Macdonald, President and Chief Executive Officer, Director (Age 56)
  • Christopher Watt, Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance (Age 51)
  • Kamalam Unninayar, Chief Financial Officer
  • Maria D. Stahl, Senior Vice President, General Counsel (Age 44)
  • Patrick T. Horn M.D. Ph.D., Chief Medical Officer (Age 61)
  • Jeffrey A. Chodakewitz M.D., Director (Age 61)
  • Geraldine A. Henwood Ph.D., Director (Age 61)
  • Garen G. Bohlin, Independent Director (Age 69)
  • John G. Freund M.D., Independent Director (Age 63)

Who owns Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Canada Pension Plan Investment Board (5.00%), Dimensional Fund Advisors LP (2.84%), JPMorgan Chase & Co. (2.33%), Candriam Luxembourg S.C.A. (0.76%), Bank of New York Mellon Corp (0.46%) and Schwab Charles Investment Management Inc. (0.42%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.

Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Canada Pension Plan Investment Board, Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc., Bank of New York Mellon Corp, Cubist Systematic Strategies LLC and Brighton Jones LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $6.15.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $316.20 million and generates $5.14 million in revenue each year. The biopharmaceutical company earns $-77,480,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. Tetraphase Pharmaceuticals employs 66 workers across the globe.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 ARSENAL STREET SUITE 110, WATERTOWN MA, 02472. The biopharmaceutical company can be reached via phone at 617-715-3600 or via email at [email protected]


MarketBeat Community Rating for Tetraphase Pharmaceuticals (TTPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.672.572.572.20
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.40$13.17$11.00$7.50
Price Target Upside: 146.58% upside107.02% upside58.96% upside5.66% downside

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Consensus Price Target History

Price Target History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017HC WainwrightReiterated RatingBuy$17.00LowView Rating Details
10/4/2017BMO Capital MarketsBoost Price TargetOutperform$13.00 -> $24.00N/AView Rating Details
9/17/2017Needham & Company LLCReiterated RatingHoldHighView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$13.00LowView Rating Details
8/28/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$14.00HighView Rating Details
11/4/2016WedbushReiterated RatingNeutral$4.00N/AView Rating Details
5/16/2016GabelliReiterated RatingNeutralN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Earnings History and Estimates Chart

Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals (NASDAQ TTPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.64)N/AView Earnings Details
11/2/2017Q3 2017($0.63)($0.63)$1.59 million$4.10 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.76)($0.83)$1.54 million$1.59 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.60)($0.79)$1.46 million$1.48 millionViewN/AView Earnings Details
3/8/2017Q4($0.60)($0.61)$1.28 million$1.09 millionViewListenView Earnings Details
11/3/2016($0.50)($0.58)$1.58 million$0.90 millionViewN/AView Earnings Details
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)$2.74 million$3.07 millionViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Earnings Estimates

2017 EPS Consensus Estimate: ($2.48)
2018 EPS Consensus Estimate: ($2.41)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.56)($0.59)
Q2 20172($0.63)($0.58)($0.61)
Q3 20172($0.76)($0.59)($0.68)
Q4 20172($0.69)($0.53)($0.61)
Q1 20181($0.61)($0.61)($0.61)
Q2 20181($0.62)($0.62)($0.62)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 58.19%
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals (NASDAQ TTPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2017L Patrick GageDirectorBuy3,880$6.45$25,026.00View SEC Filing  
10/31/2017Jacques DumasInsiderSell8,750$6.03$52,762.50View SEC Filing  
8/22/2017Jacques DumasInsiderSell17,500$6.00$105,000.00View SEC Filing  
8/17/2017Jacques DumasInsiderSell7,155$5.86$41,928.30View SEC Filing  
3/15/2017L Patrick GageDirectorBuy11,000$7.49$82,390.00View SEC Filing  
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tetraphase Pharmaceuticals (NASDAQ TTPH) News Headlines

Source:
DateHeadline
Tetraphase Pharmaceuticals (TTPH) Receives "Buy" Rating from HC WainwrightTetraphase Pharmaceuticals (TTPH) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - December 6 at 2:56 PM
Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017 - GlobeNewswire (press release)Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017 - GlobeNewswire (press release)
globenewswire.com - December 6 at 11:46 AM
Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017
finance.yahoo.com - December 6 at 11:46 AM
Contrasting Teva Pharmaceutical Industries (TEVA) and Tetraphase Pharmaceuticals (TTPH)Contrasting Teva Pharmaceutical Industries (TEVA) and Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - December 5 at 7:28 PM
Tetraphase Pharmaceuticals, Inc. (TTPH) Director L Patrick Gage Buys 3,880 SharesTetraphase Pharmaceuticals, Inc. (TTPH) Director L Patrick Gage Buys 3,880 Shares
www.americanbankingnews.com - December 4 at 11:46 AM
ValuEngine Downgrades Tetraphase Pharmaceuticals (TTPH) to Strong SellValuEngine Downgrades Tetraphase Pharmaceuticals (TTPH) to Strong Sell
www.americanbankingnews.com - December 2 at 10:28 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Recommendation of "Hold" from BrokeragesTetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 29 at 1:38 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Quarterly Sales of $2.26 MillionTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Quarterly Sales of $2.26 Million
www.americanbankingnews.com - November 28 at 2:08 PM
Stock Performance Review on Generic Drugs Industry -- pSivida, Tetraphase Pharma, Catalent, and Lannett - PR Newswire (press release)Stock Performance Review on Generic Drugs Industry -- pSivida, Tetraphase Pharma, Catalent, and Lannett - PR Newswire (press release)
www.prnewswire.com - November 22 at 1:37 PM
Financial Analysis: Tetraphase Pharmaceuticals (TTPH) & SciClone Pharmaceuticals (SCLN)Financial Analysis: Tetraphase Pharmaceuticals (TTPH) & SciClone Pharmaceuticals (SCLN)
www.americanbankingnews.com - November 21 at 3:16 PM
Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : November 20, 2017Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : November 20, 2017
finance.yahoo.com - November 20 at 11:41 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Quarterly Sales of $2.26 MillionTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Quarterly Sales of $2.26 Million
www.americanbankingnews.com - November 9 at 1:06 PM
ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 12:35 PM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.61 Per ShareTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - November 7 at 5:28 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target Increased to $17.00 by Analysts at HC WainwrightTetraphase Pharmaceuticals, Inc. (TTPH) Price Target Increased to $17.00 by Analysts at HC Wainwright
www.americanbankingnews.com - November 6 at 9:58 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) to Post FY2017 Earnings of ($2.93) Per Share, SunTrust Banks ForecastsTetraphase Pharmaceuticals, Inc. (TTPH) to Post FY2017 Earnings of ($2.93) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - November 6 at 2:10 AM
Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 5 at 7:42 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Cut to Sell at Zacks Investment ResearchTetraphase Pharmaceuticals, Inc. (TTPH) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 4 at 8:22 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Given Average Recommendation of "Hold" by BrokeragesTetraphase Pharmaceuticals, Inc. (TTPH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 4 at 1:40 AM
Tetraphase Pharmaceuticals Inc (TTPH) Insider Sells $52,762.50 in StockTetraphase Pharmaceuticals Inc (TTPH) Insider Sells $52,762.50 in Stock
www.americanbankingnews.com - November 2 at 8:54 PM
Tetraphase Pharmaceuticals Inc (TTPH) Posts  Earnings ResultsTetraphase Pharmaceuticals Inc (TTPH) Posts Earnings Results
www.americanbankingnews.com - November 2 at 7:32 PM
Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate AchievementsTetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements
finance.yahoo.com - November 2 at 10:13 AM
Tetraphase reports 3Q lossTetraphase reports 3Q loss
finance.yahoo.com - November 2 at 10:13 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Upgraded to Hold at Zacks Investment ResearchTetraphase Pharmaceuticals, Inc. (TTPH) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 28 at 9:06 AM
RSI Alert: Tetraphase Pharmaceuticals (TTPH) Now OversoldRSI Alert: Tetraphase Pharmaceuticals (TTPH) Now Oversold
www.thestreet.com - October 27 at 7:09 AM
Head to Head Review: Tetraphase Pharmaceuticals (TTPH) and Aceto Corporation (ACET)Head to Head Review: Tetraphase Pharmaceuticals (TTPH) and Aceto Corporation (ACET)
www.americanbankingnews.com - October 25 at 3:44 PM
Analyzing Tetraphase Pharmaceuticals (TTPH) & Its RivalsAnalyzing Tetraphase Pharmaceuticals (TTPH) & Its Rivals
www.americanbankingnews.com - October 25 at 3:42 PM
Tetraphase Pharmaceuticals, Inc. (TTPH) Set to Announce Earnings on WednesdayTetraphase Pharmaceuticals, Inc. (TTPH) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Generic Drugs Stocks on Investors Radar -- pSivida, Tetraphase Pharma, Catalent, and Lannett - PR Newswire (press release)Generic Drugs Stocks on Investors' Radar -- pSivida, Tetraphase Pharma, Catalent, and Lannett - PR Newswire (press release)
www.prnewswire.com - October 19 at 10:06 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.63 Per ShareTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - October 18 at 2:22 PM
Generic Drugs Stocks on Investors Radar -- pSivida, Tetraphase Pharma, Catalent, and LannettGeneric Drugs Stocks on Investors' Radar -- pSivida, Tetraphase Pharma, Catalent, and Lannett
www.bizjournals.com - October 18 at 9:49 AM
Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : October 18, 2017Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : October 18, 2017
finance.yahoo.com - October 18 at 9:49 AM
Tetraphase Pharma (TTPH) Appoints Kam Unninayar as CFOTetraphase Pharma (TTPH) Appoints Kam Unninayar as CFO
www.streetinsider.com - October 17 at 8:25 AM
Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial OfficerTetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer
finance.yahoo.com - October 17 at 8:25 AM
Analyzing Adamis Pharmaceuticals Corporation (ADMP) and Tetraphase Pharmaceuticals (TTPH)Analyzing Adamis Pharmaceuticals Corporation (ADMP) and Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - October 15 at 8:28 PM
FY2017 EPS Estimates for Tetraphase Pharmaceuticals, Inc. Decreased by Analyst (TTPH)FY2017 EPS Estimates for Tetraphase Pharmaceuticals, Inc. Decreased by Analyst (TTPH)
www.americanbankingnews.com - October 9 at 2:56 AM
Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.s Q3 2017 Earnings (TTPH)Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.'s Q3 2017 Earnings (TTPH)
www.americanbankingnews.com - October 9 at 1:02 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Rating Lowered to Hold at Zacks Investment ResearchTetraphase Pharmaceuticals, Inc. (TTPH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 7 at 11:54 PM
Tetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development ProgramTetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development Program
www.streetinsider.com - October 6 at 11:54 AM
BMO Capital Markets Boosts Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target to $24.00BMO Capital Markets Boosts Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target to $24.00
www.americanbankingnews.com - October 4 at 10:32 PM
Tetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development Program - StreetInsider.comTetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development Program - StreetInsider.com
www.streetinsider.com - October 4 at 9:27 AM
Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017
finance.yahoo.com - October 4 at 9:27 AM
Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : September 25, 2017Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : September 25, 2017
finance.yahoo.com - October 3 at 2:00 PM
Tetraphase Pharmaceuticals to Present Data at IDWeek 2017Tetraphase Pharmaceuticals to Present Data at IDWeek 2017
finance.yahoo.com - October 3 at 2:00 PM
Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : September 26, 2017Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : September 26, 2017
finance.yahoo.com - October 3 at 2:00 PM
 Analysts Anticipate Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million Analysts Anticipate Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million
www.americanbankingnews.com - October 1 at 3:38 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.56 Per ShareTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.56 Per Share
www.americanbankingnews.com - September 29 at 8:20 PM
Short Interest in Tetraphase Pharmaceuticals, Inc. (TTPH) Declines By 32.0%Short Interest in Tetraphase Pharmaceuticals, Inc. (TTPH) Declines By 32.0%
www.americanbankingnews.com - September 29 at 1:30 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by Needham & Company LLCTetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
Tetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst - Seeking AlphaTetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst - Seeking Alpha
seekingalpha.com - September 17 at 8:51 AM

SEC Filings

Tetraphase Pharmaceuticals (NASDAQ:TTPH) SEC Filings

DateFilerForm TypeView
12/04/2017
8:02 AM
GAGE L PATRICK (Reporting)
Tetraphase Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Tetraphase Pharmaceuticals (NASDAQ:TTPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tetraphase Pharmaceuticals (NASDAQ TTPH) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.